Clinical Trial

Study of Co-administered (Types 1 & 2) Novel Oral Poliomyelitis Vaccines Evaluation

Study acronym: SCOPE
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the safety and tolerability of co-administration of nOPV1 + nOPV2 in infants, relative to those receiving monovalent nOPV vaccines alone and whether two and/or three doses of co-administered nOPV1 and nOPV2 are non-inferior to corresponding doses of nOPV1 alone and nOPV2 alone.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-03-19; most recent amendment 2026-01-07.
Status change: Not Yet Recruiting → Recruiting 2026-01-07
Trial Details
NCT Number NCT06895486
Lead Sponsor PATH
Collaborators: Bill and Melinda Gates Foundation, PT Bio Farma, Centers for Disease Control and Prevention, Technical Resources International, Inc., Centro de Vacunación e Investigación (Cevaxin)
Conditions Poliomyelitis
Enrollment 675 participants
Start Date 2025-11-11
Primary Completion 2026-12-28 (estimated)
Study Completion 2026-12-28 (estimated)
Updated on ClinicalTrials.gov 2026-01-09